Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435130 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCR1 | |
| SCHEMBL15528142 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL21226786 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL3714541 | 0.79 | DAO (1.00) | DAORIPK1AURKAPARP1 | |
| SCHEMBL29756947 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCR1 | |
| SCHEMBL1574005 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1AURKB | |
| SCHEMBL668758 | 0.79 | DAO (0.65) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL9696059 | 0.78 | DAO (0.59) | DAORIPK1AURKAPARP1CCNB2 | |
| SCHEMBL745278 | 0.77 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL22185856 | 0.76 | DAO (0.61) | DAORIPK1AURKAPARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104902895-A | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | FLYNN DANIEL L | 2015-09-09 | — | — | CN | disclosed |
| US-9073920-B2 | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012024437-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | KRAS, QDPR, BTD | DAO 2376/4885RIPK1 3656/4885AURKA 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.